Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022
Curis, Inc. (NASDAQ: CRIS) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call is scheduled for the same day at 4:30 pm ET. The call can be accessed by dialing (888) 346-6389 in the U.S. or (412) 317-5252 internationally, and will also be available on Curis's website. Curis focuses on developing cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech.
- Collaboration with Genentech for Erivedge commercialization.
- Ongoing clinical trials for emavusertib with potential for further development.
- FDA placed a partial clinical hold on TakeAim Lymphoma and TakeAim Leukemia trials.
- No new patients will be enrolled during the clinical hold.
LEXINGTON, Mass., April 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET.
To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317- 5252 from other locations, shortly before 4:30 pm ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as non-Hodgkins lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Lymphoma and TakeAim Leukemia trials during which no new patients will be enrolled, and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2022-financial-results-and-hold-conference-call-on-may-5-2022-301535826.html
SOURCE Curis, Inc.
FAQ
When will Curis release its first quarter 2022 financial results?
What is the purpose of Curis's conference call on May 5, 2022?
What is the status of the clinical trials for emavusertib?
How can investors access the Curis conference call?
